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S UMM A R Y
In August 2011, the World Health Organization and the
International Union Against Tuberculosis and Lung
Disease launched the Collaborative Framework for Care
and Control of Tuberculosis (TB) and diabetes mellitus
(DM) to guide policy makers and implementers in
combatting the epidemics of both diseases. Progress has
been made, and includes identifying how best to
undertake bidirectional screening for both diseases,
how to provide optimal treatment and care for patients
with dual disease and the most suitable framework for
monitoring and evaluation. Key programmatic challeng-
es include the following: whether screening should be
directed at all patients or targeted at those with high-risk
characteristics; the most suitable technologies for
diagnosing TB and diabetes in routine settings; the best
time to screen TB patients for DM; how to provide an
integrated, coordinated approach to case management;
and finally, how to persuade non-communicable disease
programmes to adopt a cohort analysis approach,
preferably using electronic medical records, for moni-
toring and evaluation. The link between DM and TB
and the implementation of the collaborative framework
for care and control have the potential to stimulate and
strengthen the scale-up of non-communicable disease
care and prevention programmes, which may help in
reducing not only the global burden of DM but also the
global burden of TB.
K E Y WORD S : DM; TB; DM-TB interaction; bi-direc-
tional screening; programmatic challenges
IN 2007 AND 2008, two systematic reviews of the
medical literature alerted the scientific community to
the important association between diabetes mellitus
(DM) and tuberculosis (TB).1,2 The studies demon-
strated that the relative risk of TB in cohorts of DM
patients compared with normal subjects was 3.1
(95% confidence interval 2.3–4.3), and that the odds
ratios of TB occurring in persons with DM in case-
control studies varied from 1.2 to 7.8. Further
reviews have confirmed these findings, and suggest
that the overall risk of TB in persons with DM is two
to three times higher than in the general popula-
tion.3,4 Both type 1 and type 2 DM can increase the
risk of TB, but as type 2 disease accounts for790%
of DM cases worldwide, the public health burden of
comorbid disease from type 2 DM is much greater,
and this is the focus of this paper.5
Although the link between the two diseases has
been known for years from anecdotal reports, case
studies and clinical experience, the implications of
this interaction for public health were thought until
recently to be insignificant, as TB is relatively rare in
high-income countries where DM is prevalent, and
DM is perceived as being a minor problem in low-
and middle-income countries (LMICs) where TB is
epidemic. This perception has changed radically in
the last decade with the recognition of the huge,
unfolding epidemic of DM in LMICs, the slower
decline in global TB incidence than would be
expected from epidemiological modelling and a
better understanding of how DM and TB interact.
It is not clear why DM patients, particularly those
with poorly controlled disease, are at increased risk of
TB, although changes have been found in both their
innate and their adaptive immune responses.1,6 The
exact mechanisms underlying this susceptibility to TB
are still relatively undefined and are in need of detailed
evaluation. In 2012, the population attributable
fraction of DM among adult TB cases was estimated
at 15%, with the number of adult TB cases associated
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with DM being 1042000, only slightly less than
observed for human immunodeficiency virus (HIV)
associated TB.7 The top 10 countries with the highest
incidence of TB associated with DM are shown in
Table 1.
In addition to the increased risk for TB, persons
with dual disease have worse anti-tuberculosis
treatment outcomes with longer times to sputum
culture conversion, increased risk of death or
treatment failure, and increased risk of recurrent TB
after successful completion of treatment.8,9 Converse-
ly, TB, like other infections, can worsen glycaemic
control and complicate the clinical management of
DM. Bidirectional screening and integrated manage-
ment should help to improve early diagnosis,
treatment and health outcomes of both conditions.
In the light of this situation, the World Health
Organization (WHO) and the International Union
Against Tuberculosis and Lung Disease (The Union)
launched the Collaborative Framework for Care and
Control of Tuberculosis and Diabetes in August 2011
to guide policy makers and implementers in combat-
ting the TB-DM epidemic (Table 2), with emphasis on
operational (and other) research so that the evidence
base for action can be built and strengthened.10 This
has had the desired effect, with a multitude of studies
being conducted in the last few years, as a result of
which a number of programmatic issues and chal-
lenges have been and are continuing to be identified.
In the present paper, we highlight these challenges
in relation to 1) bi-directional screening of TB and
DM, 2) case management, and 3) monitoring and
evaluation.
SCREENING TUBERCULOSIS PATIENTS FOR
DIABETES MELLITUS
Where resources for DM diagnosis are available, TB
patients should be screened for DM at the start of anti-
tuberculosis treatment.10 A systematic review of bi-
directional screening for DM and TB in 2009 using
strict inclusion criteria identified 18 studies on
screening TB patients for DM, with a yield of DM
that ranged from 1.9% to 35%, suggesting that the
value of the activity depends to a large extent on where
the screening is taking place geographically.11 Since
this review, various countries have reported a high
yield from screening; these include India (especially
southern India),12–15 Pakistan,16 China,17,18 Mexi-
co,19 the United States,20 Tanzania,21 Nigeria22 and
the Republic of the Marshall Islands in the Pacific.23
However, as high yields are not always the case,24
programmes will need to decide on whether such
screening is needed and, if so, what is the most cost-
effective approach and whether targeted screening is of
better value than screening all patients. In many of the
studies cited, age .40 years, being male and living in
an urban area were significantly associated with a
higher risk of DM.13–15,20,23 In India especially, other
factors, such as smoking, past history of TB, increased
waist circumference and pulmonary disease, were also
associatedwith high rates of DM.13–15,25–27 As always,
Table 1 Top 10 countries with the highest incidence of TB associated with DM (adapted from
Lo¨nnroth et al.7)
Country
TB incidence
(all age groups)
/100000
Adults
with DM
Million
Population attributable
fraction of DM for
adult TB cases
%
Adult TB cases
associated
with DM,
n
India 176 65 15 302000
China 73 98 17 156000
South Africa 1 000 3 15 70000
Indonesia 185 9 10 48000
Pakistan 231 7 12 43000
Bangladesh 225 5 10 36000
Philippines 265 3 11 29000
Russia 91 11 17 23000
Myanmar 377 2 11 21000
Democratic Republic of Congo 327 2 10 19000
TB¼ tuberculosis; DM¼ diabetes mellitus.
Table 2 Collaborative activities to reduce the dual burden of
DM and TB (adapted from the Collaborative Framework for Care
and Control of Tuberculosis and Diabetes10)
A) Establish mechanisms for collaboration
1 Set up means of coordinating DM and TB activities
2 Conduct surveillance of TB disease prevalence among persons
with DM in medium and high TB burden settings
3 Conduct surveillance of DM prevalence in TB patients in all
countries
4 Conduct monitoring and evaluation of collaborative DM and
TB activities
B) Detect and manage TB in DM patients
1 Intensify detection of TB among persons with DM
2 Ensure TB infection control in health care settings where DM is
managed
3 Ensure high-quality anti-tuberculosis treatment and
management in DM patients
C) Detect and manage DM in TB patients
1 Screen TB patients for DM
2 Ensure high-quality DM management among TB patients
DM¼ diabetes mellitus; TB¼ tuberculosis.
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decisions about whom to screen for DM will depend
on human resources, the technology available for DM
testing and the feasibility of referral to DM clinics for
confirmation of diagnosis and care.
When and how to screen TB patients for DM are
two important programmatic issues that are yet to be
fully resolved (Table 3). Although it is logistically
easier to screen patients at the time of registration,
and this has obvious advantages such as the potential
to identify and control DM at the start of anti-
tuberculosis treatment, previous studies have shown
that TB as a chronic infectious disease may elevate
blood glucose or glycosylated haemoglobin (HbA1c)
levels, resulting in false-positive diagnoses.1,28 All
DM diagnoses made at this early stage of anti-
tuberculosis treatment should therefore be subject to
later confirmation so that the patient is not errone-
ously labelled as having a life-long non-communica-
ble disease (NCD). It is not yet known whether
transitory elevated blood glucose levels in a TB
patient are a marker for late DM, and it is advisable
to recommend future follow-up DM testing in such
patients. The most appropriate testing method for
DM in the routine setting is also not resolved. In two
large studies in India and China,12,17 TB patients
were screened at the time of registration by asking
first about the presence or absence of known DM,
and in those denying any known disease by using
random blood glucose measurements to identify
those at risk, followed by fasting blood glucose
(FBG) measurements in those needing to be further
screened. This method identified those already with
DM, who could be referred back to care for better
control of their blood glucose and those with
previously unrecognised new disease who could
benefit from earlier diagnosis and treatment. How-
ever, FBG testing has low sensitivity. In India, HbA1c
performed better as a screening tool than FBG,29 and
in a large DM prevalence study in China, screening
with FBG missed nearly half of the DM patients
diagnosed with a 2-h 75 g oral glucose tolerance
test.30 The latter test, however, is cumbersome and
inappropriate for screening individuals within routine
general health services.
In summary, HbA1c has to be the gold standard
measurement that programmes aim for, as this assesses
blood glucose levels over a period of 2–3 months
rather than on a particular day. Multiple efforts are
now underway to produce low-cost, reliable assays for
HbA1c. Other point-of-care glucose measurement
technologies are being developed, and all of these
should improve diagnostic screening in the future.31
SCREENING PERSONS WITH DIABETES
MELLITUS FOR TUBERCULOSIS
People with DM should be considered for systematic
TB screening only in countries with a TB prevalence of
over 100 per 100000 population, as the number
needed to screen to detect a new case of TB can be very
high when TB prevalence is low.10,32 How best and
how frequently this should be done at the programme
level still requires further evaluation. In India and
China, DM patients were screened for TB using a
traditional symptom screen every time the patient
visited the clinic, and those with positive symptoms
were referred to TB services for investigation, primar-
ily using sputum smearmicroscopy.33,34 This approach
resulted in high TB detection rates that varied from
300 to 800/100000 persons screened per quarter in
China to 600–950/100000 persons screened/quarter
in India. However, a large proportion of these TB cases
Table 3 Programmatic issues related to the screening of TB patients for DM
Programme issue Intervention Considerations
When to screen for DM
At time of registration Easiest time to screen. May obtain false-positive diagnosis of DM due to stress-
induced hyperglycaemia
At end of initial phase Less likely to obtain false-positive diagnosis of DM. However, early interventions to
treat DM and potentially improve treatment outcomes are lost
At end of continuation
phase
Too late to have any effect on improving anti-tuberculosis treatment outcomes if
the patient does have DM
How to screen for DM
Clinical assessment Very low sensitivity and too much overlap with clinical presentation of TB
Urine dipstick for glucose Easy and inexpensive, but low sensitivity
Capillary glucose (finger
prick)
Point of care, easy to perform, sensitivity varies depending on random or fasting
sample, results almost identical to those from plasma
Random plasma glucose Easy to perform, but sensitivity is low—needs fasting blood glucose for
confirmation
Fasting plasma glucose Most commonly used test; sensitivity varies from 66% to 85%.5 May be the most
cost-effective method due to low marginal cost
HbA1c Measures glucose levels over 2–3 months; high sensitivity; no need for fasting or
availability of 75 g glucose or 2-h waiting; expensive; affected by anaemia and
haemoglobinopathies
Oral glucose tolerance test Gold standard, but too cumbersome and time-consuming for routine use
TB¼ tuberculosis; DM¼ diabetes mellitus; HbA1c¼ glycosylated haemoglobin.
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were already diagnosed and on treatment prior to
screening; the cost-effectiveness of this approach thus
needs further detailed evaluation.
There were several other operational and program-
matic challenges, including 1) reluctance of busy DM
doctors to take on the additional work needed to
screen for TB, 2) the low sensitivity of current
pulmonary TB diagnostic approaches that rely on
sputum smear examination and chest radiography,
and 3) difficulties in diagnosing extra-pulmonary TB.
Further work is needed to determine whether
screening using chest radiography, followed by rapid
nucleic acid amplification technology for diagnosis,
such as Xpertw MTB/RIF (Cepheid, Sunnyvale, CA,
USA), is feasible, more sensitive and cost-effective.
Benefits of uniform or targeted screening should also
be evaluated. In a large tertiary care hospital for DM
in South India, important characteristics of DM
patients that put them at higher risk of TB included
older age, longer duration of DM, poor glycaemic
control, higher frequency of alcohol consumption
and lower body mass index; these characteristics
could be used to determine who especially needs to be
screened for TB.35
One simple, inexpensive, and as yet unevaluated
method is to implement a major education pro-
gramme for care givers and patients, so that persons
with DM understand the risks of TB, recognise the
symptoms and present to health care services when
they think they might have TB. Such an approach
might also help mitigate the risk of person-to-person
TB transmission within DM clinics. There is currently
Table 4 Programmatic issues related to the treatment and care of patients with both TB and DM
Programme issue Intervention Considerations
Length of anti-tuberculosis treatment
Currently 6 months for new drug-
susceptible TB: RMP, INH
pyrazinamide and EMB for the
first 2 months, followed by RMP
and INH for 4 months
Increased rates of treatment failure and recurrent TB suggest need
to consider extended treatment; this should be evaluated in
formal clinical trials
Reasons for increased failure and recurrent TB are not known and
include more extensive TB disease, altered DM immune response,
reduced concentrations of anti-tuberculosis drugs
Drug-drug interactions leading to reduced drug concentrations
RMP increases hepatic metabolism
of oral sulphonylurea derivatives,
thus reducing their plasma
concentrations and making dose
adjustments difficult
Little is known about the
interaction of RMP with newer
anti-diabetes drugs
Diabetes (due to the disease or
sulphonylurea derivatives) may
reduce plasma RMP
concentrations
Insulin and metformin are largely unaffected by RMP and should be
strongly considered if drug treatment of DM is needed
Weight-adjusted doses of anti-tuberculosis drugs might be needed,
although this is difficult to implement in routine programmatic
practice
Associated antiretroviral therapy for HIV-infected TB patients may
incur additional interactions
Drug-drug toxicity 5
INH and DM
EMB and DM
Metformin and anti-tuberculosis
drugs
All drugs
Peripheral neuropathy induced by both INH and DM. Use adjunctive
pyridoxine
EMB-induced ocular effects and DM-induced retinopathy
Gastrointestinal toxicity from metformin and anti-tuberculosis
drugs. Potentially fatal lactic acidosis from interaction with INH
There may need to be more intensive laboratory monitoring of
patients with DM and TB
Adherence to medication Adherence could be compromised
by symptoms of both diseases,
high pill counts, side effects of
drugs
Appropriate patient education, use of fixed-dose combinations of
anti-tuberculosis drugs
TB infection control Ensure DM clinics are designed for
good ventilation—open
windows, skylights
More information needed about the role of DM clinics in facilitating
transmission of Mycobacterium tuberculosis
Lifestyle modifications
Getting patients to quit smoking
and reduce alcohol consumption
Dietary advice
Exercise
Smoking and alcohol are both risk factors for TB and compromise
healthy outcomes in non-communicable diseases such as DM
The classic dietary advice for controlling DM and TB may be
conflicting: calorie restriction to lose weight (DM) vs. high
protein, high calorie intake to gain weight (TB). Health care
workers will require specific guidance to deal with this. It can also
be confusing for patients, who will require proper counselling
DM patients should have daily physical activity; when they also have
TB, this may be practically difficult due to the physical condition
of the patient. As the condition of the patient improves, gradual
increase in exercise could be introduced
TB¼ tuberculosis; DM¼ diabetes mellitus; RMP¼ rifampicin; INH¼ isoniazid; EMB¼ ethambutol; HIV¼ human immunodeficiency virus.
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no evidence to support screening for latent tubercu-
lous infection (LTBI) in DM clinics, and this approach
is not recommended in the WHO-Union Framework
nor in the recentWHO guidelines on the management
of LTBI.10,36
TREATMENT AND CARE FOR PATIENTS WITH
TUBERCULOSIS AND DIABETES MELLITUS
Most patients with dual disease are cared for by their
respective programmes. However, an integrated, co-
management approach might be a better option, and
certainly from the patients’ perspective. During the
initial phase of anti-tuberculosis treatment, there is
strict supervision and support that includes many
encounters with health care staff. There are opportu-
nities here for integrated health education and
integrated clinical management. In the TB clinic,
patients identified with DM could be referred to the
DM clinic for diagnostic confirmation and advice
about diet, exercise and drugs and then managed for
DM back at the TB clinic during the course of anti-
tuberculosis treatment. Once anti-tuberculosis treat-
ment is completed, such patients should be referred
permanently to the DM clinic, with vigilant follow-up
to identify recurrent TB. A similar approach could be
adopted for persons with DM who are diagnosed
with TB, with the management of dual disease being
centred at the TB clinic during the entire length of
anti-tuberculosis treatment. This would require dis-
cussion, education, training and resources directed at
the TB clinics, but as with HIV-associated TB this
would be better for the patient, who would be
regarded as one person with two diseases.
There are still uncertainties about the optimum
treatment strategies in patients with dual disease; some
of the key issues are highlighted in Table 4. Extended
anti-tuberculosis treatment in DM patients is used in
some places, and this has been the subject of some
recent published research.37 However, the evidence for
extending treatment beyond 6 months is weak, no
randomised controlled trials have assessed whether
extended or otherwise changed treatment regimens are
more effective than standardised regimens, and the
WHO does not recommend such a policy. It would
seem sensible in those with dual disease to avoid
sulphonylurea derivatives and treat DM with diet,
lifestyle modifications, metformin and insulin instead,
as these last two medications have little interaction
with anti-tuberculosis drugs.5 There is also prelimi-
nary evidence to suggest that metformin may be an
effective adjunct to anti-tuberculosis treatment by
augmenting protective host-immune responses.38 Pe-
ripheral neuropathy from isoniazid can often be
prevented by giving pyridoxine 12.5 mg daily, and
this should always be administered in the presence of
concurrent DM. Finally, little is known about facility-
based TB transmission in DM clinics. In Mexico, 20%
of DM patients with recurrent TB had re-infection
with a different strain of Mycobacterium tuberculo-
sis,9 and it is possible that recurrent disease may result
from inadvertent exposure to undiagnosed TB in DM
clinics.
MONITORING AND EVALUATION
The cornerstone of good TB control programmes is a
standardised monitoring and evaluation system pro-
viding quarterly reports on the number of patients
registered for anti-tuberculosis treatment, the types
and categories of TB and their treatment outcomes. It
has thus been relatively easy to build into this system
a monitoring and evaluation framework for DM
screening, similar to what is currently being done for
HIV/AIDS (acquired immune-deficiency syndrome)
and antiretroviral therapy.39 In the large studies in
Figure 1 Page of a Tuberculosis-Diabetes Register showing how TB patients were screened for DM and the results recorded at TB
Units, in India (adapted from 12). TB¼ tuberculosis; DM¼ diabetes mellitus; Y¼ yes; N¼ no; RBG¼ random blood glucose; FBG¼
fasting blood glucose.
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India and China,12,17 TB patients were screened for
DM according to a set algorithm, and results were
recorded in a separate TB-DM register linked to the
main TB patient register through TB registration
numbers (Figure 1). The same format was used to
prepare quarterly reports on aggregate data, provide
an understanding of what steps worked and the
results of each screening component. However, the
quantity of data provided in such a monitoring and
evaluation system is too much for a national TB
Figure 2 Recording of results of DM screening in A) the back of the TB treatment card and B) the right hand page of the patient TB
register in India after the country had adopted a policy of screening all TB patients for DM. HIV¼human immunodeficiency virus; DM¼
diabetes mellitus; DMC¼ designated microscopy centre; CPT¼cotrimoxazole preventive therapy; ART¼antiretroviral therapy; H¼
isoniazid; R¼ rifampicin; E¼ ethambutol; MO¼Medical Officer; FBS¼ fasting blood sugar.
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programme that simply wants to know howmany TB
patients were screened, how many were diagnosed
with DM, how many were referred for DM care and
what the treatment outcomes were. Figure 2 (A and
B) shows how this information was integrated into
the TB treatment cards and TB patient registers in
India after the country had made a policy decision in
2012 to screen all TB patients for DM.
Recording the results of screening DM patients for
TB has been a much more difficult exercise, largely
due to the absence of any globally established cohort
reporting systems for patients with chronic NCDs. In
India and China, treatment cards for persons with
DM were developed and used in clinics to record the
outcomes of clinic visits, and in particular who had
been screened for TB, who had positive symptoms
suggestive of TB, who were referred for TB investi-
gations and who were diagnosed with TB (Figure
3).33,34 This monitoring system captured the number
of DM patients attending the clinic each quarter, but
in many cases this included the same patients who had
attended the clinic in previous quarters. However,
because the clinics had not adopted any formal system
for registering their patients, the cumulative number
of patients ever registered, which increased each
quarter as new patients were added to the pool, was
not known. It was therefore not possible to obtain the
patient denominators that are so crucial to calculate
case detection rates. The answer lies in persuading
NCD programmes to adopt a formal cohort analysis
approach. This has been successfully used in hospitals
in Malawi and primary health care clinics in the Near
East,40,41 and deserves wider recognition.
CONCLUSION
Given the accepted link between DM and TB and the
escalating global burden of DM, which is set to
exceed 500 million people by 2030, the inclusion of
DM in strategic plans to control TB will become
increasingly important in the next few years. More
evidence is required to answer important questions
about bi-directional screening in different settings,
optimal treatment and care and integration of
services, which could lead to better TB prevention,
earlier diagnosis and start of treatment for DM and
improved health outcomes for those with dual
disease. The link between DM and TB and the
framework for collaborative activities have the
potential to stimulate and strengthen the implemen-
tation and scale-up of NCD care and prevention
programmes. This may help not only to reduce the
burden of non-communicable and communicable
disease, it could also be a driver to strengthen health
systems, a necessary pre-requisite for establishing
universal health coverage. High-level political sup-
port within countries as well as international finan-
cial and technical support for disease programmes
will be essential to move this agenda forward.
Conflicts of interest: none declared.
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R E S U M E
En aouˆt 2011, l’Organisation Mondiale de la Sante´ et
l’Union Internationale Contre la Tuberculose et
Maladies Respiratoires ont lance´ le Cadre Collaboratif
pour la Prise en charge de la Tuberculose (TB) et du
Diabe`te (DM) et la lutte contre ces maladies afin de
guider les responsables des politiques et les responsables
de la mise en œuvre dans leur combat contre ces deux
e´pide´mies. Des progre`s ont e´te´ re´alise´s et incluent la
recherche de la meilleure manie`re d’entreprendre le
de´pistage des deux maladies a` la fois, la fac¸on d’offrir un
traitement et des soins optimaux aux patients atteints
des deux maladies et le cadre le plus adapte´ pour le suivi
et l’e´valuation. Les de´fis programmatiques principaux
incluent les questions suivantes : le ciblage du de´pistage
pour tous les patients ou seulement ceux qui pre´sentent
des caracte´ristiques de risque e´leve´ ; les techniques les
plus adapte´es au diagnostic de la TB et du DM en
contexte de routine ; le meilleur moment de de´pister un
DM chez les patients ; la manie`re de fournir une
approche inte´gre´e et coordonne´e a` la prise en charge
des cas ; et finalement la fac¸on de persuader les
programmes de maladies non transmissibles d’adopter
une approche d’analyse de cohorte, en utilisant de
pre´fe´rence des dossiers me´dicaux e´lectroniques, pour le
suivi et l’e´valuation. Le lien entre DM et TB et la mise en
œuvre du Cadre Collaboratif pour les soins et la lutte ont
le potentiel de stimuler et de renforcer l’expansion des
programmes de traitement et de pre´vention des maladies
non transmissibles, ce qui pourrait contribuer a` re´duire
non seulement le poids global du DM mais e´galement le
fardeau de la TB.
R E S UM E N
En agosto del 2011, la Organizacio´n Mundial de la
Salud y la Unio´n Internacional Contra la Tuberculosis y
Enfermedades Respiratorias pusieron en marcha un
Marco de Colaboracio´n para la Atencio´n y Control de
la Tuberculosis (TB) y la Diabetes (DM), con el objeto
de orientar a las instancias encargadas de formular las
polı´ticas y de ponerlas en pra´ctica, en materia de lucha
contra la epidemia de ambas enfermedades. Se han
logrado progresos en la determinacio´n de los mejores
mecanismos de deteccio´n sistema´tica bidireccional de
ambas enfermedades, el suministro o´ptimo de
tratamiento y atencio´n a estos pacientes y en la
definicio´n del marco ma´s conveniente de seguimiento y
evaluacio´n. Los aspectos programa´ticos fundamentales
que plantean dificultades consisten en decidir si la
deteccio´n sistema´tica debe abarcar a todos los
pacientes o si debe dirigirse a los que presentan
caracterı´sticas de alto riesgo; escoger las te´cnicas
diagno´sticas ma´s adaptadas al diagno´stico de la TB y
la DM en la pra´ctica corriente; definir el momento ma´s
oportuno para investigar la DM en los pacientes con
diagno´stico de TB; escoger el mejor me´todo para ofrecer
un enfoque integrado y coordinado del tratamiento de
los casos; y por u´ltimo, persuadir a los encargados de los
programas de enfermedades no transmisibles de que
adopten la estrategia del ana´lisis de cohortes, de
preferencia a partir de los registros me´dicos
informatizados, con fines de seguimiento y evaluacio´n
de los pacientes. El establecimiento del vı´nculo entre la
DM y la TB y la introduccio´n de un marco de trabajo
conjunto de atencio´n y control pueden fomentar y
reforzar la ampliacio´n de escala de los programas de
atencio´n y prevencio´n de las enfermedades no
transmisibles y con ello no solo se disminuira´ la carga
mundial de morbilidad por DM, sino tambie´n la carga
mundial de la TB.
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